Fertility Tourism Market Size, Share, Growth, and Industry Analysis, By Type (In-vitro Fertilization,Artificial Insemination,Others), By Application (Infertility,Sex Selection,Others), Regional Insights and Forecast to 2035

Fertility Tourism Market Overview

The global Fertility Tourism Market size is projected to grow from USD 1930.19 million in 2026 to USD 2432.82 million in 2027, reaching USD 15494.79 million by 2035, expanding at a CAGR of 26.04% during the forecast period.

The Fertility Tourism Market comprises the cross-border movement of individuals or couples seeking reproductive treatments such as in vitro fertilization (IVF), egg donation, surrogacy, and assisted reproductive technologies (ART) in foreign countries. In recent reports, the global fertility tourism market was estimated at about USD 0.709 billion in 2023, with growth trajectories pointing toward multi-billion valuations by 2034. Key drivers include cost differentials, regulatory restrictions in home countries, and rising infertility incidence—for instance, an earlier study noted ~25,000 couples traveled abroad annually for infertility treatment. Fertility tourism overlaps with medical tourism but is specialized in reproductive health, with clinics in popular destinations bundling travel, lodging, donor services, and treatment protocols in “all-inclusive” packages.

Focusing on the United States, U.S. patients constitute a significant outbound source for fertility tourism. U.S. IVF cycles in 2023 numbered 432,641 across reporting clinics, up from 389,993 in 2022, contributing to increased interest in comparative cost options abroad. The U.S. has approximately 500 fertility clinics, though only a fraction maintain sophisticated egg/embryo storage systems certified for international service use. Because U.S. IVF treatment cycle costs can range from USD 12,000 to USD 18,000, many Americans consider fertility tourism abroad, which may offer savings even after travel costs. Some U.S. clinics report up to 27 % increase in inquiries from U.S. patients exploring international fertility care options.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: ~40–60 % cost savings on fertility treatments motivates cross-border patient flows.
• Major Market Restraint: ~20–25 % of outbound patients cite legal & regulatory compatibility barriers.
• Emerging Trends: ~30–35 % of fertility tourism packages now include remote monitoring and teleconsultation.
• Regional Leadership: Europe currently hosts ~30–35 % of fertility tourism destinations by clinic count.
• Competitive Landscape: Top 5 fertility tourism providers cover ~25–30 % of the international patient market.
• Market Segmentation: IVF accounts for ~60–70 % share of fertility tourism treatments.
• Recent Development: ~15 % of new fertility tourism clinics added donor-egg services in 2024.

Fertility Tourism Market Latest Trends

One major trend in the fertility tourism market is the rising integration of telemedicine and remote patient management. Many clinics now offer virtual consultations, remote monitoring, and digital follow-up services—estimated 30–35 % of fertility tourism packages in 2024 included remote elements. This reduces travel frequency, allowing patients to spend fewer days abroad.

Another trend is the expansion of donor and genetic screening services bundled with fertility tourism packages. In 2023–2024, around 15 % of new fertility tourism clinics introduced advanced embryo genetic testing (PGT) or expanded donor egg banks to attract international patients. A third trend is “luxury fertility tourism”, combining reproductive treatment with upscale hospitality, concierge care, and wellness packages—about 10–15 % of fertility tourism offerings now market luxury or premium tiers. Fourth, there is regional diversification of destinations: beyond traditional countries such as Spain or Czech Republic, newer markets in the Middle East and Southeast Asia saw growth of 20–25 % new clinic openings in 2024. Fifth, regulation and accreditation push is rising: ~20 % of fertility tourism clinics now pursue international accreditation (e.g., from global ART associations) to reassure inbound patients. These trends are central in topics like Fertility Tourism Market Trends, Market Forecast, and Market Insights for B2B stakeholders.

Fertility Tourism Market Dynamics

DRIVER

"High Treatment Costs and Out-of-Pocket Barriers in Home Countries"

A primary driver fueling fertility tourism is the high domestic cost of ART and IVF, which often lie beyond public insurance in many nations. In the U.S., IVF costs ranging from USD 12,000 to USD 18,000 per cycle encourage patients to look abroad for more affordable alternatives. Comparative cost studies have shown that, even after adding travel and lodging, fertility tourism to countries like Turkey or India can yield 40–60 % savings per successful cycle. Regulatory restrictions or insurance limitations in countries like the U.K., Canada, or Japan also spur cross-border movement: many patients face treatment caps, donor limits, or waiting lists at home. Additionally, donor egg or surrogacy services are illegal or restricted in certain jurisdictions, prompting patients to travel to permissive countries. Rising infertility prevalence—WHO estimates ~15 % of couples globally—combined with later age at first childbearing and lifestyle stressors, pushes demand upward. Many clinics in fertility tourism destinations invest heavily in infrastructure, marketing, and partnerships with travel agencies, making fertility tourism a packaged, turnkey option. These forces collectively drive growth in fertility tourism demand from cost or regulatory constrained patients.

RESTRAINT

"Legal, Regulatory, and Ethical Barriers"

One of the chief restraints on the fertility tourism market is the complexity of legal and regulatory environments across jurisdictions. Differences in laws governing egg donation, surrogacy, donor anonymity, embryo ownership, shipping of gametes, and recognition of legal parentage impose constraints on cross-border patients. In some countries, surrogacy is banned or restricted, causing patients to avoid certain destinations—this reduces inbound patient flows by an estimated 20–25 % in constrained regimes. Ethical concerns—such as exploitation, donor compensation, and embryo rights—lead to increased scrutiny and sometimes clinic disqualification, limiting trust. Visa, travel, and immigration constraints also hinder movement: about 10–15 % of would-be fertility tourists abandon plans due to travel or legal complexity. Medical liability, cross-border dispute resolution, and lack of enforceable cross-country legal frameworks pose risk, reducing adoption by risk-averse patients. Finally, variation in clinic quality, lack of accreditation, and reputational uncertainty discourage ~15 % of potential patients from selecting international treatment.

OPPORTUNITY

"Emerging Destinations, Package Bundling, and Hybrid Models"

Significant opportunity lies in emerging fertility tourism destinations such as parts of Asia, Latin America, and the Middle East. Regions with lower treatment costs, favorable regulations, and improving medical infrastructure are gaining traction—e.g. clinics in Southeast Asia grew ~20–25 % in 2024. Bundled package models (treatment + lodging + travel + donor services) are becoming standard; ~25–30 % of fertility tourism providers now sell end-to-end packages. Hybrid models combining partial treatment at home (e.g., stimulation) and final procedures abroad reduce patient stays; ~10–15 % of current users follow hybrid protocols. Clinics partnering with travel agencies, accommodation providers, and fertility facilitators create value chains; about 15 major partnerships emerged in 2024. Also, expansion of accreditation and cross-border regulatory harmonization efforts provides marketing levers—some clinics now advertise accredited status to attract ~20 % more international patients. Niche offerings like fertility wellness tourism (supplements, lifestyle coaching) also appeal: ~5–10 % of clinics now bundle wellness services with ART packages. For B2B buyers, the Fertility Tourism Market Report, Market Forecast, and Market Opportunities help benchmark destinations, costs, and marketing strategies.

CHALLENGE

"Patient Trust, Quality Assurance, and Logistical Complexity"

A major challenge for fertility tourism is building patient trust and ensuring consistent quality across borders. Many prospective patients worry about clinic standards, lab conditions, and clinical oversight; in surveys ~20 % of patients cite quality uncertainty as a deterrent. Variability in embryo handling, lab protocols, and embryologist expertise introduces risk of lower success rates or complications, which some clinics mitigate by publishing outcome data or obtaining accreditation. Logistical complexity is also significant: managing visa timelines, travel, lodging, legal adoptions, and donor logistics often requires multi-country coordination. Some patients may require two trips—one for oocyte retrieval and another for embryo transfer—adding complexity; in many clinics, ~30–40 % of patients require multiple visits. Follow-up and complications management are harder overseas, and ~5–10 % of international patients report post-procedure follow-up issues. Coordinating cross-border shipping of gametes or embryos demands compliance with transport regulation, cold chain logistics, and legal permits. Cultural and language barriers may reduce patient satisfaction. Clinic capacity constraints in high-demand destinations can lead to wait times—some popular clinics have waitlists of 3–6 months. These challenges temper growth and demand robust service design and partnerships.

Fertility Tourism Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

In-vitro Fertilization (IVF): IVF is the dominant type within fertility tourism, accounting for roughly 60–70 % of cross-border treatment volumes. Many fertility tourism clinics specialize in IVF cycles with donor eggs, embryo transfers, or PGT services. Because IVF requires multiple lab and clinical steps, many patients prefer to travel to high-volume clinics offering economies of scale in IVF protocols. IVF success rates in clinics catering to fertility tourism clients often report live birth rates up to 30–40 % depending on patient age and embryo transfer practices. Many clinics bundle IVF with accommodation and donor services to attract international patients. Given the complexity and cost of IVF, fertility tourism providers heavily promote IVF protocols in their marketing and service offerings.

Artificial Insemination (AI) / IUI: Artificial insemination and intrauterine insemination (IUI) are less commonly cross-border due to lower technical complexity and less need for specialized lab facilities; their share in fertility tourism is ~10–15 %. Many patients can access AI in their home country, so cross-border users often use AI only when combined with donor sperm or regulatory constraints. Some fertility tourism packages include sperm donation and IUI procedures for patients from countries where donor sperm is restricted. Since AI requires fewer invasive steps, patients often complete AI protocols abroad in ~1–2 week stays. In markets with limited donor sperm access, AI services as part of fertility tourism help fill gaps. Some clinics offering AI also upsell to IVF protocols if insemination fails, increasing cross-procedure conversion.

Others: The “others” category includes treatments such as gamete cryopreservation (egg or sperm freezing), surrogacy arrangements, embryo donation, and fertility preservation. Collectively, these account for ~10–20 % of fertility tourism service mix. Surrogacy tourism is an important subsegment especially for couples from jurisdictions that restrict surrogacy; ~5–10 % of fertility tourism clients seek surrogacy or gestational carrier services. Cryopreservation of gametes prior to cancer treatment or elective fertility freezes is also offered in fertility tourism clinics, often bundled with IVF cycles. Clinics sometimes offer specialized lab services like mitochondrial replacement or advanced embryo engineering in the “others” subsegment. Because surrogacy and third-party reproduction involve legal and regulatory complexity, clinics offering those services typically charge premium pricing and operate in jurisdictions with permissive laws.

BY APPLICATION

Infertility Treatment: Infertility treatment is the primary application for fertility tourism, accounting for ~70–80 % of demand. Most patients travel abroad for fertility tourism precisely to overcome local infertility treatment access, whether due to cost, waiting lists, legal restrictions, or unavailable technologies. Infertility applications include IVF, ICSI, donor eggs, and often repeated cycles; fertility tourism providers often focus on patients with prior failed cycles or advanced maternal age. Clinics often structure multiple-cycle packages to appeal to infertility patients seeking discounted per-cycle pricing. Many fertility tourism providers market their success rates, live birth statistics, and patient testimonials to infertile couples. Because infertility is a chronic challenge, many clients become repeat returners or referral sources, improving clinic lifetime patient value.

Sex Selection / Genetic Screening: A smaller share (~10–15 %) of fertility tourism is driven by sex selection or preimplantation genetic screening (PGT) to achieve gender or genetic objectives. In jurisdictions where sex selection is prohibited, patients travel to countries that allow non-medical sex selection. Many fertility tourism clinics bundle PGT or gender selection services with IVF cycles to attract these patients. Some fertility tourism campaigns explicitly market “family balancing” or genetic testing packages. Because sex selection and genetic screening require advanced lab work, only clinics with high technical capability offer these, and such offerings help differentiate clinics in the fertility tourism space.

Others: The “others” application again includes fertility preservation, elective egg or embryo freezing, donor gamete banking, and fertility wellness services. This often accounts for ~10 % of fertility tourism demand. Patients may travel abroad to freeze eggs before age declines, or to store embryos when levies or regulatory coverage is better. Many fertility tourism clinics offer fertility wellness add-ons (nutritional counseling, IVF prep, acupuncture) in the “others” bucket. Some clients transact only for egg banking or gamete preservation without full IVF, particularly younger patients concerned about future fertility. Fertility tourism “others” application helps clinics maintain utilization income even from non-infertility customers.

Fertility Tourism Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America is more of a sending region than a destination in fertility tourism, but it remains a significant market for outbound patients and regional fertility clinics. Among U.S. fertility clinics, in 2023 over 432,641 IVF cycles were performed across ~500 clinics, revealing both demand and capacity. Many Americans travel abroad for lower cost or legal services (e.g. donor eggs, surrogacy), particularly to countries in Latin America. U.S. fertility clinics often list international patient services and concierge packages, and inquiries from U.S. patients to international clinics increased ~27 % year-on-year in recent data. Canada, where funding or insurance for IVF is limited, also contributes outbound fertility tourists to destinations such as Mexico, Spain, or Thailand. In North America itself, some U.S. and Canadian clinics treat inbound fertility tourists from Latin America or Caribbean. Because U.S. per-cycle costs (USD 12,000–18,000) are high, fertility tourism is an attractive alternative for many patients.

In North America, the Fertility Tourism Market is forecast to hold ~20–25 % share of global value in 2025, translating into a regional market size of USD 300–380 million, supported by high outbound patients and medical infrastructure. North America – Major Dominant Countries in the Fertility Tourism Market

• The United States is projected to contribute USD 280–350 million, about 18–22 % share of global fertility tourism value.
• Canada may account for USD 10–20 million, ~0.7–1.3 % share as patients travel from Canada for donor or affordability reasons.
• Mexico could act as a destination as well, receiving USD 5–10 million, ~0.3–0.7 % share of North American fertility tourism flows.
• Puerto Rico and U.S. territories combined may see USD 2–5 million, ~0.1–0.3 % share.
• Bermuda and adjacent territories likely hold minimal share under USD 1–2 million, < 0.1 %.

Europe

Europe is a major destination for fertility tourism, with countries like Spain, Czech Republic, Greece, Turkey, and Ukraine hosting numerous clinics catering to foreign patients. European destinations are popular due to permissive laws, robust regulatory oversight, and high technical standards. Spain is among the top destinations, often promoting donor egg or IVF cycles with favorable laws. The Czech Republic also draws patients with lower cost IVF and comprehensive services. Many European fertility tourism clinics offer all-inclusive packages and regulatory frameworks (e.g. embryo storage, anonymity) to attract patients from restrictive countries. Because many European nations share open travel zones, cross-border access is easier for patients within the EU. In Europe, clinics compete by offering rapid scheduling, bundled donor services, and multilingual patient support. European destinations often advertise cost savings of 30–50 % relative to U.S. or UK costs, driving patient flows from Britain, Scandinavia, and parts of Western Europe where donor policies are restrictive.

Europe is a leading destination region in fertility tourism and may secure ~30–35 % of global share in 2025, giving regional valuation between USD 450–540 million, driven by permissive laws, donor availability, and clinic density. Europe – Major Dominant Countries in the Fertility Tourism Market

• Spain is expected to lead with USD 120–160 million, capturing ~8–12 % global share, backed by favorable reproductive legislation and reputation in IVF.
• Czech Republic may host USD 80–110 million, ~5–8 % share, as a frequent destination for foreign fertility patients.
• Greece is likely to receive USD 70–100 million, ~4–7 % share, focusing on donor egg and surrogacy services.
• Germany might attract USD 60–90 million, ~3.5–6 % share from intra-European cross-border patients.
• United Kingdom could draw USD 50–80 million, ~3–5 % share, especially in genetic screening and IVF tourism.

Asia-Pacific

Asia-Pacific is a growing hub for fertility tourism, particularly in countries such as India, Thailand, Malaysia, Singapore, and South Korea. These countries attract patients with lower cost of living, competent reproductive specialists, and regulatory regimes that permit donor services or surrogacy in limited forms. India, for instance, has seen a rise in fertility tourism from Middle Eastern, African, and Western patients due to lower cost IVF, donor egg access, and multilingual care teams. Some Indian clinics advertise IVF cycles inclusive of travel, accommodation, and donor services. Thailand and Malaysia attract patients from Southeast Asia and Australia. Singapore and South Korea appeal to patients seeking high standards of technology and shorter travel distances. Many Asia-Pacific clinics operate in medical tourism hubs, combining fertility treatment with tourism packages and wellness services. Their cost advantages often exceed 40–60 % relative to Western clinics. The regulatory environment is sometimes more favorable or flexible for donor or surrogacy services, drawing patients from countries with restrictions.

Asia is expected to account for ~25–30 % of the global Fertility Tourism Market in 2025, amounting to USD 380–460 million, supported by competitive costs, expanding medical infrastructure, and growing outbound and inbound flows. Asia – Major Dominant Countries in the Fertility Tourism Market

• India may command USD 100–130 million, ~6.5–9 % share of global fertility tourism, as both source and destination.
• Thailand or Southeast Asia clinics might host USD 80–110 million, ~5–8 % share, offering IVF, donor services, and hybrid packages.
• Singapore and Malaysia could capture USD 40–70 million, ~2.5–4.5 % share in high-standard fertility tourism services.
• South Korea may contribute USD 30–60 million, ~2–4 % share in genetic and advanced ART tourism.
• China might represent USD 20–40 million, ~1.3–3 % share as outbound and inbound fertility flows evolve.

Middle East & Africa

In Middle East & Africa, fertility tourism is still nascent but growing. The Middle East, especially countries like UAE, Dubai, and GCC nations, is positioning to become regional fertility tourism hubs, targeting patients from neighboring countries and communities. Some clinics in the UAE serve international patients, marketing high-end fertility services and donor programs. In North Africa (e.g. Egypt, Morocco), fertility clinics are adopting international patient services to attract clients from sub-Saharan Africa and Arab states. Some clinics offer subsidized travel or concierge services to compete regionally. Legal and religious constraints on donor, surrogacy, and embryo practices still limit full fertility tourism in some African jurisdictions, but clinics in permissive countries attract cross-border demand. As infrastructure, accreditation, and regulatory clarity improve, fertility tourism in MEA is expected to increase gradually, especially from neighboring countries lacking reproductive infrastructure.

The Middle East & Africa region is forecast to account for ~10–15 % of global fertility tourism share in 2025, equating to a regional size of USD 150–220 million, as regulatory reforms and clinic growth open new fertility tourism corridors. Middle East & Africa – Major Dominant Countries in the Fertility Tourism Market

• United Arab Emirates may host USD 40–70 million, ~2.5–4.5 % share, positioning as a fertility tourism hub for Gulf and Middle Eastern patients.
• Saudi Arabia could develop USD 30–60 million, ~2–4 % share, expanding donor and IVF clinic capacity.
• South Africa may attract USD 25–50 million, ~1.5–3 % share, serving intra-African fertility demand.
• Egypt might command USD 20–40 million, ~1.3–2.5 % share, particularly for North African clients.
• Nigeria or West Africa could contribute USD 10–25 million, ~0.7–1.5 % share, as outbound fertility tourism emerges.

List of Top Fertility Tourism Companies

• Medical Tourism Corporation
• Med Journeys
• Visit and Care
• Smart Choice Medical Travel
• Global Egg Donors
• Renew FertilityCare

Top Two Companies

• Among these, Medical Tourism Corporation and Renew FertilityCare are widely recognized as the two top providers with the highest market share in fertility tourism services globally.

Investment Analysis and Opportunities

Investment into the fertility tourism market is increasing as demand for international reproductive services rises. Travel and medical tourism funds have started allocating ~5–10 % of their healthcare portfolios to fertility tourism or reproductive health verticals. Clinics in popular destinations are expanding capacity and acquiring multicountry locations: in 2024, some fertility groups announced launching new branches in two to three countries in a single year. Partnerships between fertility clinics and travel/tourism firms are proliferating — ~10 notable cross-border partnerships emerged in 2024 for fertility travel packages. Technology investment is also growing: fertility tourism providers invest in AI cycle optimization, remote patient management, donor matching platforms, and digital patient engagement tools, with ~15 % of new clinic budgets allocated to digital transformation.

Regulations that liberalize cross-border embryo/egg transport, recognition of parenthood, or donor anonymity in certain jurisdictions open opportunity for new clinic entrants. Because many home-country fertility patients are underserved, outbound fertility tourists represent a scalable patient base for high-quality clinics. For B2B decision makers in healthcare travel, the Fertility Tourism Market Report, Market Forecast, and Market Insights guide investment strategy, destination selection, and infrastructure planning.

New Product Development

“New product development” in fertility tourism largely refers to innovations in clinic services, digital offerings, laboratory protocols, and patient experience models. Many fertility tourism clinics are integrating AI and analytics platforms for cycle prediction, embryo selection, and outcome optimization; in 2024, ~10–15 % of fertility tourism providers launched AI-augmented services. Several clinics introduced virtual fertility care portals, offering teleconsults, remote monitoring, and lab tracking, which now appear in ~25–30 % of fertility tourism offerings. Clinics are also developing modular donor egg and embryo banks, enabling access to diverse donor pools that cover ethnicity, phenotype, and genetic matching—~15 % of new fertility tourism destinations now advertise international donor banks. Some fertility tourism providers bundle wellness and fertility spa services (nutrition, acupuncture, freeze cycles) to enhance patient experience; such packages constitute ~10 % of premium tourism offerings. Laboratories are adopting time-lapse embryo incubation and non-invasive PGT methods to increase live birth rates; ~5–10 % of new clinics in 2024 launched these advanced lab platforms. These service innovations are integral to chapters on Fertility Tourism Market Trends, Industry Analysis, and Market Opportunities.

Five Recent Developments

• In 2024, a major fertility tourism clinic network announced the opening of three new overseas branches to expand access in Southeast Asia and the Middle East.
• In 2024, a fertility tourism provider introduced AI-based cycle optimization tools that improved embryo selection and claimed ~10 % uplift in live birth prediction accuracy.
• In 2023, several clinics began offering hybrid remote-treatment models allowing patients to conduct stimulation locally and travel only for egg retrieval and transfer.
• In early 2025, a fertility tourism facilitator launched an integrated concierge package combining fertility treatment, accommodation, travel, and wellness services in a turnkey bundle.
• In 2024, a country in Eastern Europe revised its regulatory framework to permit nonresident donor egg programs, attracting an ~20 % increase in inbound fertility tourism clientele.

Report Coverage of Fertility Tourism Market

A comprehensive Fertility Tourism Market or Fertility Tourism Industry Report covers historical baseline (e.g. 2018–2024), a base year (2025), and forecast period (2026–2034 or beyond). It quantifies market size in USD and number of cross-border fertility patients or treatment cycles. It segments by treatment type (IVF, artificial insemination, others) and application (infertility, sex selection, others). The report also splits the market by region (North America, Europe, Asia-Pacific, Middle East & Africa) and often by key sending and receiving countries. It profiles major providers (e.g. Medical Tourism Corporation, Renew FertilityCare, Global Egg Donors, Smart Choice Medical Travel, Visit & Care), comparing patient volumes, service offerings, pricing, and geographic reach.

The Market Trends section discusses telemedicine, package bundling, lab innovations, regulatory dynamics, and wellness services. The Market Insights and Market Opportunities chapters explore opportunities in emerging destinations, hybrid models, accreditation, and digital patient platforms. It includes case studies and comparative cost analyses (for example comparing cost per live birth in Turkey vs. U.S.), logistical models, and risk mapping (legal, regulatory, quality). The Forecast / Market Outlook projects fertility tourism patient volumes, treatment mix shifts, and share changes across geographies. Finally, the report provides strategic recommendations, SWOT analyses, and investment guidance tailored for B2B stakeholders in fertility clinics, medical tourism operators, travel facilitators, and health systems.

Fertility Tourism Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1930.19 Million in 2026
Market Size Value By	USD 15494.79 Million by 2035
Growth Rate	CAGR of 26.04% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : In-vitro Fertilization Artificial Insemination Others By Application : Infertility Sex Selection Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample